Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Vaccines and Therapeutic Proteins Research Group, the Special Task Force for Activating Research (STAR), Chulalongkorn University, Bangkok 10330, Thailand.
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. doi: 10.12932/AP-200220-0772.
As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.
随着世界正在见证由新型冠状病毒 SARS-CoV-2 引起的 COVID-19 疫情,新兴的遗传学和临床证据表明,其与 SARS 和 MERS 有类似的发展路径。快速的基因组测序和开放获取数据,以及先进的疫苗技术,有望让我们在不久的将来对病原体本身有更多的了解,包括宿主免疫反应和治疗性疫苗的方案。本综述旨在对 SARS-CoV、MERS-CoV 和新出现的 SARS-CoV-2 进行比较,希望更好地了解宿主-病原体相互作用、宿主免疫反应以及病原体免疫逃避策略。这种预测性的观点可能有助于设计针对 COVID-19 的免疫干预或预防性疫苗。